REGENXBIO Inc. Class Action Lawsuit - RGNX
Case Summary
Investors who suffered a loss and would like to learn more, click here to contact us.
The REGENXBIO class action lawsuit seeks to represent purchasers or acquirers of REGENXBIO Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). Captioned Kuik v. REGENXBIO Inc., No. 26-cv-00611 (D. Md.), the REGENXBIO class action lawsuit charges REGENXBIO and certain of REGENXBIO’s top current and former executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the REGENXBIO class action lawsuit, please provide your information in the form on this page. You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com. Lead plaintiff motions for the REGENXBIO class action lawsuit must be filed with the court no later than April 14, 2026.
CASE ALLEGATIONS: REGENXBIO is a clinical-stage biotechnology company that provides gene therapies that deliver functional genes to cells with genetic defects. REGENXBIO is developing product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I (MPS I), also known as Hurler syndrome.
The REGENXBIO class action lawsuit alleges that defendants throughout the Class Period disseminated false and misleading statements and/or concealing material adverse facts concerning the efficacy and safety of its RGX-111 trial study.
The REGENXBIO investor class action lawsuit alleges that on January 28, 2026. REGENXBIO announced that the U.S. Food & Drug Administration placed a clinical hold on its investigational gene therapy RGX-111. In pertinent part, defendants allegedly announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study. On this news, the price of REGENXBIO fell nearly 18%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired REGENXBIO securities during the Class Period to seek appointment as lead plaintiff in the REGENXBIO class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the REGENXBIO investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the REGENXBIO shareholder class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the REGENXBIO class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.